BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

PLoS By Category | Recent PLoS Articles
Immunology - Infectious Diseases - Pathology - Respiratory Medicine

Effect of Different Interferona2 Preparations on IP10 and ET-1 Release from Human Lung Cells
Published: Monday, October 08, 2012
Author: Rekha Badiger et al.

by Rekha Badiger, Jane A. Mitchell, Hime Gashaw, Neil A. Galloway-Phillipps, Stefan Foser, Fernando Tatsch, Thomas Singer, Trevor T. Hansel, Tobias Manigold

Background

Alfa-interferons (IFNa2a, IFNa2b, 40KDa-PEGIFNa2a and 12KDa-PEGIFNa2b) are effective treatments for chronic hepatitis C infection. However, their usage has been associated with a variety of adverse events, including interstitial pneumonitis and pulmonary arterial hypertension. Although rare, these adverse events can be severe and potentially life-threatening, emphasizing the need for simple biomarkers of IFN-induced lung toxicity.

Methods

Human lung microvascular endothelial cells (HLMVEC), human pulmonary artery smooth muscle (HPASM) cells and A549 cells were grown under standard conditions and plated into 96- or 6-well plates. Cells were stimulated with various concentrations of different IFNs in hydrocortisone-free medium. After 24 and 48 hours, IP10 and ET-1 were measured by ELISA in conditioned medium. In a second set of experiments, cells were pre-treated with tumour necrosis factor-a (TNF-a) (10 ng/mL).

Results

IFNa2a, IFNa2b, 40KDa-PEGIFNa2a and 12KDa-PEGIFNa2b, but not IFN?, induced IP10 (CXCL10) release and increased IP10 gene induction in HLMVEC. In addition, all four IFNa preparations induced IP10 release from HPASM cells and A549 cells pre-treated with TNFa. In each of these cell types, 40KDa-PEGIFNa2a was significantly less active than the native forms of IFNa2a, IFNa2b or 12KDa-PEGIFNa2b. Similarly, IFNa2a, IFNa2b and 12KDa-PEGIFNa2b, but not 40KDa-PEGIFNa2a, induced endothelin (ET)-1 release from HPASM cells.

Conclusions

Consistent with other interstitial pulmonary diseases, both IP10 and ET1 may serve as markers to monitor IFN-induced lung toxicity in patients. In addition, both markers may also serve to help characterize the risk associated with IFNa preparations to induce lung toxicity.

  More...